Identification

Name
Clozapine
Accession Number
DB00363  (APRD00470)
Type
Small Molecule
Groups
Approved
Description

A tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. [PubChem]

Structure
Thumb
Synonyms
  • Clozapin
  • Clozapina
  • Clozapine
  • Clozapinum
External IDs
HF 1854 / HF-1854 / LX 100-129 / W 108
Product Ingredients
IngredientUNIICASInChI Key
Clozapine hydrochloride80862U56A354241-01-9ARWPDHKDEREYEE-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Aa-clozapineTablet200 mgOralAa Pharma Inc2017-02-27Not applicableCanada
Aa-clozapineTablet25 mgOralAa Pharma Inc2004-01-27Not applicableCanada
Aa-clozapineTablet100 mgOralAa Pharma Inc2004-01-27Not applicableCanada
Aa-clozapineTablet50 mgOralAa Pharma Inc2017-02-27Not applicableCanada
Auro-clozapineTablet50 mgOralAuro Pharma IncNot applicableNot applicableCanada
Auro-clozapineTablet25 mgOralAuro Pharma IncNot applicableNot applicableCanada
Auro-clozapineTablet100 mgOralAuro Pharma IncNot applicableNot applicableCanada
Auro-clozapineTablet200 mgOralAuro Pharma IncNot applicableNot applicableCanada
ClozapineTablet, orally disintegrating150 mg/1OralTeva2015-05-05Not applicableUs
ClozapineTablet25 mg/1OralSandoz2016-05-06Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ClozapineTablet25 mg/1OralActavis Pharma Company2015-12-22Not applicableUs
ClozapineTablet25 mg/1OralAurobindo Pharma2016-11-29Not applicableUs
ClozapineTablet50 mg/1OralSun Pharmaceutical Industries Limited2005-08-19Not applicableUs
ClozapineTablet100 mg/1OralMayne Pharma2016-08-03Not applicableUs
ClozapineTablet25 mg/1OralTeva2007-05-10Not applicableUs00093 4359 01 nlmimage10 2f2d97fc
ClozapineTablet100 mg/1OralAvera Mc Kennan Hospital2016-01-08Not applicableUs
ClozapineTablet100 mg/1OralTeva2009-09-18Not applicableUs00093 7772 01 nlmimage10 242d1278
ClozapineTablet100 mg/1OralAvera Mc Kennan Hospital2015-08-12Not applicableUs
ClozapineTablet200 mg/1OralAurobindo Pharma2016-11-29Not applicableUs
ClozapineTablet, orally disintegrating25 mg/1OralMylan Pharmaceuticals2015-11-02Not applicableUs
International/Other Brands
Azaleptine (Arpimed) / Cloment (Pharmaplan) / Clonex (Adeka) / Clopin (East West) / Clopine (Douglas) / Clopsine (Psicofarma) / Clorazem (Remedica) / Lanolept (Lannacher) / Lapenax (Novartis) / Leponex (Novartis) / Lodux (Rider) / Lozapin (Torrent) / Luften (Pharos) / Mezapin (Panbiotic) / Refract (Crescent) / Refraxol (AC Farma) / Sensipin (Beximco) / Sequax (Ivax) / Sizopin (Sun) / Sizopril (Meprofarm) / Syclop (Brown & Burk Phils) / Syzopin (Psyco Remedies) / Tanyl (Novamed) / Uspen (Yu Sheng) / Zapen (Psipharma) / Zapenia (Incepta) / Zapine (Taiwan Biotech) / Ziproc (Torrent) / Zopin (Psychotropics India)
Categories
UNII
J60AR2IKIC
CAS number
5786-21-0
Weight
Average: 326.823
Monoisotopic: 326.129824335
Chemical Formula
C18H19ClN4
InChI Key
QZUDBNBUXVUHMW-UHFFFAOYSA-N
InChI
InChI=1S/C18H19ClN4/c1-22-8-10-23(11-9-22)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3
IUPAC Name
6-chloro-10-(4-methylpiperazin-1-yl)-2,9-diazatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,9,11,13-heptaene
SMILES
CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12

Pharmacology

Indication

For use in patients with treatment-resistant schizophrenia.

Structured Indications
Pharmacodynamics

Clozapine is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives and is indicated for the treatment of schizophrenia. Clozapine is a selective monoaminergic antagonist with high affinity for the serotonin Type 2 (5HT2), dopamine Type 2 (D2), 1 and 2 adrenergic, and H1 histaminergic receptors. Clozapine acts as an antagonist at other receptors, but with lower potency. Antagonism at receptors other than dopamine and 5HT2 with similar receptor affinities may explain some of the other therapeutic and side effects of Clozapine. Clozapine's antagonism of muscarinic M1-5 receptors may explain its anticholinergic effects. Clozapine's antagonism of histamine H1 receptors may explain the somnolence observed with this drug. Clozapine's antagonism of adrenergic a1 receptors may explain the orthostatic hypotension observed with this drug.

Mechanism of action

Clozapine's antipsychotic action is likely mediated through a combination of antogistic effects at D2 receptors in the mesolimbic pathway and 5-HT2A receptors in the frontal cortex. D2 antagonism relieves positive symptoms while 5-HT2A antagonism alleviates negative symptoms.

TargetActionsOrganism
AD(2) dopamine receptor
antagonist
Human
A5-hydroxytryptamine receptor 2A
antagonist
Human
UD(1A) dopamine receptor
antagonist
Human
UD(3) dopamine receptor
antagonist
Human
UD(4) dopamine receptor
antagonist
Human
U5-hydroxytryptamine receptor 1A
antagonist
Human
U5-hydroxytryptamine receptor 1B
antagonist
Human
U5-hydroxytryptamine receptor 1D
antagonist
Human
U5-hydroxytryptamine receptor 1E
antagonist
Human
U5-hydroxytryptamine receptor 2C
antagonist
Human
U5-hydroxytryptamine receptor 3A
antagonist
Human
U5-hydroxytryptamine receptor 6
antagonist
Human
U5-hydroxytryptamine receptor 7
antagonist
Human
NHistamine H1 receptor
antagonist
Human
NHistamine H4 receptor
antagonist
Human
NAlpha-1A adrenergic receptor
antagonist
Human
NAlpha-1B adrenergic receptor
antagonist
Human
NAlpha-2A adrenergic receptor
antagonist
Human
NAlpha-2B adrenergic receptor
antagonist
Human
NAlpha-2C adrenergic receptor
antagonist
Human
NMuscarinic acetylcholine receptor M1
antagonist
Human
NMuscarinic acetylcholine receptor M2
antagonist
Human
NMuscarinic acetylcholine receptor M3
antagonist
Human
NMuscarinic acetylcholine receptor M4
antagonist
Human
NMuscarinic acetylcholine receptor M5
antagonist
Human
UNeuron-specific vesicular protein calcyon
unknown
Human
UGlutathione S-transferase PNot AvailableHuman
Absorption

Rapid and almost complete

Volume of distribution
Not Available
Protein binding

97% (bound to serum proteins)

Metabolism

Hepatic

Route of elimination

Approximately 50% of the administered dose is excreted in the urine and 30% in the feces.

Half life

8 hours (range 4-12 hours)

Clearance
Not Available
Toxicity

Clozapine carries a black-box warning for agranulocytosis.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3---(T;T)TT alleleADR Directly StudiedPatients with this genotype have increased weight gain with clozapine.Details
Cytochrome P450 2D6CYP2D6*3Not AvailableC alleleEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*4Not AvailableC alleleEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*5Not AvailableWhole-gene deletionEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*6Not Available1707delTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*7Not Available2935A>CEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*8Not Available1758G>TEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*11Not Available883G>CEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*12Not Available124G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*13Not AvailableCYP2D7/2D6 hybrid gene structureEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*14ANot Available1758G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*15Not Available137insT, 137_138insTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*19Not Available2539_2542delAACTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*20Not Available1973_1974insGEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*21Not Available2573insCEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*31Not Available-1770G>A / -1584C>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*36Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*38Not Available2587_2590delGACTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*40Not Available1863_1864ins(TTT CGC CCC)2Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*42Not Available3259_3260insGTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*44Not Available2950G>CEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*47Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*51Not Available-1584C>G / -1235A>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*56Not Available3201C>TEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*57Not Available100C>T / 310G>T  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*62Not Available4044C>TEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*68ANot Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*68BNot AvailableSimilar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4.Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*69Not Available2988G>A / -1426C>T  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*92Not Available1995delCEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*100Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*101Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer.Details

Interactions

Drug Interactions
DrugInteractionDrug group
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Clozapine.Investigational
2,5-Dimethoxy-4-ethylamphetamineClozapine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineClozapine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineClozapine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Clozapine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Clozapine is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Clozapine can be increased when it is combined with Abiraterone.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Clozapine.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Clozapine is combined with Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Clozapine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Clozapine is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Clozapine can be increased when it is combined with Acetaminophen.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Clozapine.Withdrawn
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Clozapine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Clozapine is combined with Adipiplon.Investigational
AfatinibThe serum concentration of Clozapine can be increased when it is combined with Afatinib.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Clozapine is combined with Agomelatine.Approved, Investigational
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Clozapine.Experimental
AjmalineThe metabolism of Ajmaline can be decreased when combined with Clozapine.Approved
AlaproclateThe serum concentration of Clozapine can be increased when it is combined with Alaproclate.Experimental
AlbendazoleThe serum concentration of Clozapine can be increased when it is combined with Albendazole.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Clozapine.Approved
AldosteroneThe serum concentration of Clozapine can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Clozapine can be increased when it is combined with Alectinib.Approved
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Clozapine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Clozapine is combined with Alfaxalone.Vet Approved
AlfentanilThe serum concentration of Clozapine can be increased when it is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Clozapine.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Clozapine is combined with Aliskiren.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Clozapine.Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Clozapine is combined with Allopregnanolone.Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Clozapine.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Clozapine.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Clozapine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Clozapine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Clozapine.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Clozapine.Approved, Withdrawn
AltretamineThe risk or severity of adverse effects can be increased when Altretamine is combined with Clozapine.Approved
AmantadineThe therapeutic efficacy of Amantadine can be decreased when used in combination with Clozapine.Approved
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Clozapine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Clozapine is combined with Amiloride.Approved
Aminohippuric acidThe serum concentration of Clozapine can be increased when it is combined with Aminohippuric acid.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Clozapine.Approved, Withdrawn
AmiodaroneThe metabolism of Clozapine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Clozapine is combined with Amisulpride.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Clozapine.Approved
AmlodipineThe serum concentration of Clozapine can be increased when it is combined with Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Clozapine is combined with Amobarbital.Approved, Illicit
AmoxapineAmoxapine may increase the QTc-prolonging activities of Clozapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Clozapine is combined with Amperozide.Experimental
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Clozapine.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Clozapine.Approved, Investigational
AmprenavirThe serum concentration of Clozapine can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe risk or severity of adverse effects can be increased when Amsacrine is combined with Clozapine.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Clozapine is combined with Amyl Nitrite.Approved
AnagrelideClozapine may increase the QTc-prolonging activities of Anagrelide.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Clozapine.Approved
ApomorphineThe therapeutic efficacy of Apomorphine can be decreased when used in combination with Clozapine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Clozapine is combined with Apraclonidine.Approved
AprepitantThe serum concentration of Clozapine can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Clozapine.Approved
ArformoterolArformoterol may increase the QTc-prolonging activities of Clozapine.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Clozapine.Approved, Investigational
ArmodafinilThe metabolism of Clozapine can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Clozapine.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Clozapine.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Clozapine.Approved
ArticaineThe risk or severity of adverse effects can be increased when Clozapine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Asenapine.Approved
AstemizoleThe serum concentration of Clozapine can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe metabolism of Clozapine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Clozapine can be increased when it is combined with Atenolol.Approved
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Clozapine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Clozapine is combined with Atorvastatin.Approved
AzacitidineThe risk or severity of adverse effects can be increased when Azacitidine is combined with Clozapine.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Clozapine is combined with Azaperone.Vet Approved
AzelastineClozapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Clozapine is combined with Azilsartan medoxomil.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Clozapine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Clozapine is combined with Baclofen.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Clozapine.Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Clozapine.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Clozapine is combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Clozapine.Approved
BedaquilineClozapine may increase the QTc-prolonging activities of Bedaquiline.Approved
BelinostatThe risk or severity of adverse effects can be increased when Belinostat is combined with Clozapine.Approved, Investigational
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Clozapine.Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Clozapine is combined with Benazepril.Approved, Investigational
BendamustineThe risk or severity of adverse effects can be increased when Bendamustine is combined with Clozapine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Clozapine is combined with Bendroflumethiazide.Approved
BenperidolThe risk or severity of adverse effects can be increased when Clozapine is combined with Benperidol.Investigational
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Clozapine.Approved
BenzocaineThe serum concentration of Clozapine can be increased when it is combined with Benzocaine.Approved
BenzphetamineClozapine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Clozapine.Approved
BepridilThe serum concentration of Clozapine can be increased when it is combined with Bepridil.Approved, Withdrawn
BetaxololThe metabolism of Clozapine can be decreased when combined with Betaxolol.Approved
BevacizumabThe risk or severity of adverse effects can be increased when Bevacizumab is combined with Clozapine.Approved, Investigational
BexaroteneThe risk or severity of adverse effects can be increased when Bexarotene is combined with Clozapine.Approved, Investigational
BiperidenThe serum concentration of Clozapine can be increased when it is combined with Biperiden.Approved
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Clozapine.Approved
BlinatumomabThe risk or severity of adverse effects can be increased when Blinatumomab is combined with Clozapine.Approved
BMS-906024The risk or severity of adverse effects can be increased when BMS-906024 is combined with Clozapine.Investigational
BoceprevirThe metabolism of Clozapine can be decreased when combined with Boceprevir.Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Clozapine.Approved, Investigational
BosentanThe serum concentration of Clozapine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe risk or severity of adverse effects can be increased when Bosutinib is combined with Clozapine.Approved
BretyliumThe risk or severity of adverse effects can be increased when Clozapine is combined with Bretylium.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Clozapine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Clozapine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Clozapine.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Clozapine is combined with Bromisoval.Experimental
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Clozapine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Clozapine is combined with Bromperidol.Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Clozapine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Clozapine is combined with Brotizolam.Approved, Withdrawn
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Clozapine.Withdrawn
BufuralolThe metabolism of Bufuralol can be decreased when combined with Clozapine.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Clozapine is combined with Bumetanide.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Clozapine.Approved, Investigational
BuprenorphineClozapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Clozapine can be decreased when combined with Bupropion.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Clozapine.Approved
BuspironeThe serum concentration of Clozapine can be increased when it is combined with Buspirone.Approved, Investigational
BusulfanThe risk or severity of adverse effects can be increased when Busulfan is combined with Clozapine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Clozapine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Clozapine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Clozapine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Clozapine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Clozapine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Clozapine is combined with Butorphanol.Approved, Illicit, Vet Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Clozapine.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Clozapine.Approved
CaffeineThe serum concentration of Clozapine can be increased when it is combined with Caffeine.Approved
CamazepamThe risk or severity of adverse effects can be increased when Camazepam is combined with Clozapine.Approved, Illicit
CanagliflozinThe risk or severity of adverse effects can be increased when Clozapine is combined with Canagliflozin.Approved
Candesartan cilexetilThe serum concentration of Clozapine can be increased when it is combined with Candesartan.Approved
CanertinibThe risk or severity of adverse effects can be increased when Clozapine is combined with Canertinib.Investigational
CapecitabineThe risk or severity of adverse effects can be increased when Capecitabine is combined with Clozapine.Approved, Investigational
CaptoprilThe serum concentration of Clozapine can be increased when it is combined with Captopril.Approved
CarbamazepineCarbamazepine may increase the myelosuppressive activities of Clozapine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Clozapine.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Clozapine is combined with Carbinoxamine.Approved
CarboplatinThe risk or severity of adverse effects can be increased when Carboplatin is combined with Clozapine.Approved
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Clozapine.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Clozapine is combined with Carfentanil.Illicit, Vet Approved
CarfilzomibThe risk or severity of adverse effects can be increased when Carfilzomib is combined with Clozapine.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Clozapine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Clozapine is combined with Carisoprodol.Approved
CarmustineThe risk or severity of adverse effects can be increased when Carmustine is combined with Clozapine.Approved
CarteololThe metabolism of Carteolol can be decreased when combined with Clozapine.Approved
CarvedilolThe serum concentration of Clozapine can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Clozapine can be increased when it is combined with Caspofungin.Approved
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Clozapine.Experimental
CE-326597The risk or severity of adverse effects can be increased when CE-326597 is combined with Clozapine.Investigational
CelecoxibThe metabolism of Clozapine can be decreased when combined with Celecoxib.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Clozapine.Approved, Vet Approved
CeritinibThe serum concentration of Clozapine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Clozapine.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Clozapine is combined with Cetirizine.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Clozapine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Clozapine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlorambucilThe risk or severity of adverse effects can be increased when Chlorambucil is combined with Clozapine.Approved
ChloramphenicolThe risk or severity of adverse effects can be increased when Chloramphenicol is combined with Clozapine.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Clozapine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Clozapine is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Clozapine is combined with Chloroprocaine.Approved
ChloroquineClozapine may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Clozapine is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Clozapine.Approved
ChlorphentermineClozapine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineClozapine may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Clozapine can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Clozapine can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Clozapine is combined with Chlorthalidone.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Clozapine.Approved
CholecalciferolThe metabolism of Clozapine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Clozapine can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Clozapine can be decreased when it is combined with Cholic Acid.Approved
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Clozapine.Experimental
CilazaprilThe serum concentration of Clozapine can be increased when it is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Clozapine.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Clozapine.Approved
CimetidineThe serum concentration of Clozapine can be increased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Clozapine can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Clozapine is combined with Cinchocaine.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Clozapine.Approved
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Clozapine.Approved, Investigational
CisaprideClozapine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CisplatinThe risk or severity of adverse effects can be increased when Cisplatin is combined with Clozapine.Approved
CitalopramThe serum concentration of Clozapine can be increased when it is combined with Citalopram.Approved
CladribineThe risk or severity of adverse effects can be increased when Cladribine is combined with Clozapine.Approved, Investigational
ClarithromycinClozapine may increase the QTc-prolonging activities of Clarithromycin.Approved
ClemastineThe metabolism of Clozapine can be decreased when combined with Clemastine.Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Clozapine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clozapine is combined with Clidinium.Approved
ClobazamThe metabolism of Clozapine can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Clozapine.Approved, Investigational
ClofazimineThe serum concentration of Clozapine can be increased when it is combined with Clofazimine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Clozapine is combined with clomethiazole.Investigational
ClomipramineClomipramine may increase the QTc-prolonging activities of Clozapine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Clozapine.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Clozapine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clozapine is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Clozapine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Clozapine can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Clozapine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Clozapine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Clozapine.Approved, Illicit
ColchicineThe serum concentration of Clozapine can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Clozapine can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Clozapine can be increased when it is combined with Conivaptan.Approved, Investigational
CrisaboroleThe metabolism of Clozapine can be decreased when combined with Crisaborole.Approved
CrizotinibClozapine may increase the QTc-prolonging activities of Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Clozapine is combined with Cyclizine.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Clozapine.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Clozapine.Approved, Investigational
CyclosporineThe metabolism of Clozapine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Clozapine is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Clozapine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
CytarabineThe risk or severity of adverse effects can be increased when Cytarabine is combined with Clozapine.Approved, Investigational
DabrafenibThe serum concentration of Clozapine can be decreased when it is combined with Dabrafenib.Approved
DacarbazineThe risk or severity of adverse effects can be increased when Dacarbazine is combined with Clozapine.Approved, Investigational
DaclatasvirThe serum concentration of Clozapine can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe risk or severity of adverse effects can be increased when Dactinomycin is combined with Clozapine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Clozapine is combined with Dantrolene.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Clozapine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Clozapine is combined with Dapiprazole.Approved
DapoxetineThe serum concentration of Clozapine can be increased when it is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Clozapine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Clozapine can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Clozapine.Approved
DasatinibThe serum concentration of Clozapine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe risk or severity of adverse effects can be increased when Daunorubicin is combined with Clozapine.Approved
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Clozapine.Approved
DecitabineThe risk or severity of adverse effects can be increased when Decitabine is combined with Clozapine.Approved, Investigational
DeferasiroxThe serum concentration of Clozapine can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Clozapine.Approved
DelavirdineThe metabolism of Clozapine can be decreased when combined with Delavirdine.Approved
DelorazepamThe risk or severity of adverse effects can be increased when Delorazepam is combined with Clozapine.Approved, Illicit
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Clozapine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Clozapine is combined with Deramciclane.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Clozapine.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Clozapine.Approved
DesloratadineThe serum concentration of Clozapine can be increased when it is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe serum concentration of Clozapine can be increased when it is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Clozapine is combined with Detomidine.Vet Approved
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Clozapine.Approved, Investigational
DexamethasoneThe serum concentration of Clozapine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Clozapine is combined with Dexbrompheniramine.Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Clozapine.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Clozapine.Approved, Illicit, Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Clozapine is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Clozapine.Approved
DexrazoxaneThe risk or severity of adverse effects can be increased when Dexrazoxane is combined with Clozapine.Approved, Withdrawn
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Clozapine.Approved, Illicit
DextromethorphanThe serum concentration of Clozapine can be increased when it is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Clozapine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Clozapine is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Clozapine is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Clozapine.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Clozapine can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Clozapine is combined with Diclofenamide.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Clozapine is combined with Diethyl ether.Experimental
DiethylpropionClozapine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Clozapine is combined with Difenoxin.Approved, Illicit
DigoxinThe serum concentration of Clozapine can be decreased when it is combined with Digoxin.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Clozapine.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Clozapine.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Clozapine.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Clozapine.Experimental
DihydroergotamineThe metabolism of Clozapine can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Clozapine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Clozapine is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Clozapine can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Clozapine is combined with Dimenhydrinate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Clozapine.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Clozapine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Clozapine is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe serum concentration of Clozapine can be increased when it is combined with Dipyridamole.Approved
DisopyramideClozapine may increase the QTc-prolonging activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Clozapine is combined with Dixyrazine.Experimental
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Clozapine.Approved, Investigational
DofetilideClozapine may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronClozapine may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneThe metabolism of Domperidone can be decreased when combined with Clozapine.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Clozapine.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Clozapine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Clozapine is combined with Doramectin.Vet Approved
DosulepinThe serum concentration of Clozapine can be increased when it is combined with Dosulepin.Approved
DoxazosinThe serum concentration of Clozapine can be increased when it is combined with Doxazosin.Approved
DoxefazepamThe risk or severity of adverse effects can be increased when Doxefazepam is combined with Clozapine.Experimental
DoxepinDoxepin may increase the QTc-prolonging activities of Clozapine.Approved
DoxorubicinThe risk or severity of adverse effects can be increased when Doxorubicin is combined with Clozapine.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Clozapine.Approved, Investigational
DoxycyclineThe metabolism of Clozapine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Clozapine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Clozapine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Clozapine.Approved, Illicit
DronedaroneThe metabolism of Clozapine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Clozapine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Clozapine is combined with Drotebanol.Experimental, Illicit
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Clozapine.Approved
DuloxetineThe serum concentration of Clozapine can be increased when it is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Clozapine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Clozapine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Clozapine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Clozapine is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Clozapine is combined with Efonidipine.Approved
ElbasvirThe serum concentration of Clozapine can be increased when it is combined with Elbasvir.Approved
EletriptanThe metabolism of Eletriptan can be decreased when combined with Clozapine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Clozapine.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Clozapine is combined with Eltanolone.Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Clozapine is combined with Empagliflozin.Approved
EnalaprilThe serum concentration of Clozapine can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Clozapine is combined with Enalaprilat.Approved
EnasidenibThe serum concentration of Clozapine can be increased when it is combined with Enasidenib.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Clozapine.Approved, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Clozapine.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Clozapine is combined with Enflurane.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Clozapine is combined with Entacapone.Approved, Investigational
EpinastineThe metabolism of Epinastine can be decreased when combined with Clozapine.Approved, Investigational
EpirubicinThe risk or severity of adverse effects can be increased when Epirubicin is combined with Clozapine.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Clozapine is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Clozapine is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Clozapine is combined with Eprosartan.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Clozapine.Approved
ErgonovineThe serum concentration of Clozapine can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Clozapine can be increased when it is combined with Ergotamine.Approved
EribulinThe risk or severity of adverse effects can be increased when Eribulin is combined with Clozapine.Approved, Investigational
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Clozapine.Approved, Investigational
ErythromycinThe metabolism of Clozapine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe serum concentration of Clozapine can be increased when it is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Clozapine can be decreased when combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Clozapine.Investigational
EsmololThe risk or severity of adverse effects can be increased when Clozapine is combined with Esmolol.Approved
EsomeprazoleThe metabolism of Clozapine can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Clozapine.Approved, Illicit
EstramustineThe serum concentration of Clozapine can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Clozapine can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Clozapine can be decreased when it is combined with Estrone.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Clozapine is combined with Eszopiclone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Clozapine is combined with Etacrynic acid.Approved
EthanolClozapine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Clozapine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Clozapine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Clozapine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Clozapine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Clozapine is combined with Ethyl chloride.Experimental
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Clozapine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Clozapine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Clozapine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Clozapine is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Clozapine.Approved
EtomidateThe risk or severity of adverse effects can be increased when Clozapine is combined with Etomidate.Approved
EtoperidoneThe serum concentration of Clozapine can be increased when it is combined with Etoperidone.Approved
EtoposideThe risk or severity of adverse effects can be increased when Etoposide is combined with Clozapine.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Clozapine.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Clozapine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Clozapine can be increased when it is combined with Etravirine.Approved
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Clozapine.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Clozapine.Approved, Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Clozapine.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Clozapine.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Clozapine.Approved
FelodipineThe serum concentration of Clozapine can be increased when it is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Clozapine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Clozapine is combined with Fenoldopam.Approved
FentanylThe serum concentration of Clozapine can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Clozapine.Approved
FexofenadineThe serum concentration of Clozapine can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Clozapine can be increased when it is combined with Fidaxomicin.Approved
FimasartanThe risk or severity of adverse effects can be increased when Clozapine is combined with Fimasartan.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Clozapine.Approved, Investigational
FlecainideClozapine may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Clozapine is combined with Flibanserin.Approved
FloxuridineThe risk or severity of adverse effects can be increased when Floxuridine is combined with Clozapine.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Clozapine is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Clozapine can be decreased when combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Clozapine.Approved
FludarabineThe risk or severity of adverse effects can be increased when Fludarabine is combined with Clozapine.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Clozapine.Approved, Illicit
FlumazenilThe risk or severity of adverse effects can be increased when Flumazenil is combined with Clozapine.Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Clozapine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Clozapine.Approved, Illicit
FluorouracilThe risk or severity of adverse effects can be increased when Fluorouracil is combined with Clozapine.Approved
FluoxetineThe serum concentration of Clozapine can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Clozapine can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Clozapine can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Clozapine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Clozapine is combined with Fluspirilene.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Clozapine is combined with Fluticasone propionate.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Clozapine.Approved
FluvoxamineThe serum concentration of Clozapine can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Clozapine.Approved, Investigational
FosamprenavirThe metabolism of Clozapine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Clozapine can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Clozapine.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Clozapine is combined with Fosinopril.Approved
FosphenytoinThe serum concentration of Clozapine can be decreased when it is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Clozapine is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Clozapine.Approved, Investigational
FurosemideThe risk or severity of adverse effects can be increased when Clozapine is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Clozapine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Clozapine is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Clozapine is combined with Gabapentin Enacarbil.Approved
Gadobenic acidClozapine may increase the QTc-prolonging activities of Gadobenic acid.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Clozapine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Clozapine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GefitinibThe serum concentration of Clozapine can be increased when it is combined with Gefitinib.Approved, Investigational
GemcitabineThe risk or severity of adverse effects can be increased when Gemcitabine is combined with Clozapine.Approved
GemfibrozilThe metabolism of Clozapine can be decreased when combined with Gemfibrozil.Approved
GemifloxacinClozapine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
Gemtuzumab ozogamicinThe risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Clozapine.Approved
GenisteinThe serum concentration of Clozapine can be increased when it is combined with Genistein.Investigational
GepefrineClozapine may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Clozapine is combined with Gepirone.Investigational
GlecaprevirThe serum concentration of Clozapine can be increased when it is combined with Glecaprevir.Approved
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Clozapine.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Clozapine.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Clozapine.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Clozapine.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Clozapine.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Clozapine is combined with Glutethimide.Approved, Illicit
GlyburideThe serum concentration of Clozapine can be increased when it is combined with Glyburide.Approved
GlycerinThe serum concentration of Clozapine can be increased when it is combined with Glycerin.Approved, Investigational
GoserelinGoserelin may increase the QTc-prolonging activities of Clozapine.Approved
Gramicidin DThe serum concentration of Clozapine can be increased when it is combined with Gramicidin D.Approved
GranisetronClozapine may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GrepafloxacinThe serum concentration of Clozapine can be increased when it is combined with Grepafloxacin.Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Clozapine is combined with Guanfacine.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Clozapine.Investigational
HalazepamThe risk or severity of adverse effects can be increased when Clozapine is combined with Halazepam.Approved, Illicit, Withdrawn
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Clozapine.Approved
HaloperidolClozapine may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Clozapine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Clozapine is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Clozapine is combined with Hexobarbital.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Clozapine.Approved
HydralazineThe risk or severity of adverse effects can be increased when Clozapine is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Clozapine is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneClozapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Clozapine can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Clozapine is combined with Hydroflumethiazide.Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Clozapine.Approved, Illicit
HydroxyamphetamineClozapine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyureaThe risk or severity of adverse effects can be increased when Hydroxyurea is combined with Clozapine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Clozapine.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Clozapine.Approved, Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Clozapine.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Clozapine.Approved
IbutilideClozapine may increase the QTc-prolonging activities of Ibutilide.Approved
IdarubicinThe risk or severity of adverse effects can be increased when Idarubicin is combined with Clozapine.Approved
IdelalisibThe serum concentration of Clozapine can be increased when it is combined with Idelalisib.Approved
IfosfamideThe risk or severity of adverse effects can be increased when Ifosfamide is combined with Clozapine.Approved
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Clozapine.Approved
IloprostThe risk or severity of adverse effects can be increased when Clozapine is combined with Iloprost.Approved, Investigational
ImatinibThe risk or severity of adverse effects can be increased when Imatinib is combined with Clozapine.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Clozapine is combined with Imidapril.Investigational
ImipramineImipramine may increase the QTc-prolonging activities of Clozapine.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Clozapine.Approved
IndalpineThe serum concentration of Clozapine can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Clozapine.Approved
IndinavirThe metabolism of Clozapine can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Clozapine is combined with Indiplon.Investigational
IndomethacinThe serum concentration of Clozapine can be increased when it is combined with Indomethacin.Approved, Investigational
IndoraminThe risk or severity of adverse effects can be increased when Clozapine is combined with Indoramin.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Clozapine.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Clozapine.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Clozapine.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Clozapine.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Clozapine.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Clozapine.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Clozapine.Approved
Interferon alfa-n3The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Clozapine.Approved, Investigational
Interferon alfacon-1The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Clozapine.Approved
Iofetamine I-123Clozapine may decrease the stimulatory activities of Iofetamine I-123.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Clozapine.Approved
IrbesartanThe metabolism of Clozapine can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe risk or severity of adverse effects can be increased when Irinotecan is combined with Clozapine.Approved, Investigational
IsavuconazoniumThe metabolism of Clozapine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Clozapine.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Clozapine.Approved, Vet Approved
IsoniazidThe metabolism of Clozapine can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Clozapine is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Clozapine is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Clozapine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the QTc-prolonging activities of Clozapine.Approved
ItraconazoleThe metabolism of Clozapine can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Clozapine.Approved
IvacaftorThe serum concentration of Clozapine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Clozapine can be increased when it is combined with Ivermectin.Approved, Vet Approved
IxabepiloneThe risk or severity of adverse effects can be increased when Ixabepilone is combined with Clozapine.Approved, Investigational
IxazomibThe metabolism of Ixazomib can be decreased when combined with Clozapine.Approved
KetamineThe serum concentration of Clozapine can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Clozapine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Clozapine is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Clozapine can be decreased when combined with Ketoconazole.Approved, Investigational
L-PhenylalanineThe risk or severity of adverse effects can be increased when L-Phenylalanine is combined with Clozapine.Approved, Nutraceutical
LabetalolThe metabolism of Labetalol can be decreased when combined with Clozapine.Approved
LacidipineThe risk or severity of adverse effects can be increased when Clozapine is combined with Lacidipine.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Clozapine is combined with Lamotrigine.Approved, Investigational
LansoprazoleThe serum concentration of Clozapine can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Clozapine.Approved, Investigational
LeflunomideThe metabolism of Clozapine can be decreased when combined with Leflunomide.Approved, Investigational
LenalidomideThe risk or severity of adverse effects can be increased when Lenalidomide is combined with Clozapine.Approved
LenvatinibClozapine may increase the QTc-prolonging activities of Lenvatinib.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Clozapine is combined with Lercanidipine.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Clozapine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Clozapine is combined with Levetiracetam.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Clozapine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Clozapine is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Clozapine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Clozapine is combined with Levocetirizine.Approved
LevodopaClozapine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinClozapine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Clozapine is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe serum concentration of Clozapine can be increased when it is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Clozapine is combined with Levorphanol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Clozapine is combined with Levosimendan.Approved, Investigational
LevothyroxineThe serum concentration of Clozapine can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Clozapine can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Clozapine.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Clozapine.Approved, Investigational
LiothyronineThe serum concentration of Clozapine can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Clozapine can be decreased when it is combined with Liotrix.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Clozapine.Approved
LisdexamfetamineClozapine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe serum concentration of Clozapine can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Clozapine.Approved
LithiumLithium may increase the neurotoxic activities of Clozapine.Approved
LobeglitazoneThe metabolism of Clozapine can be decreased when combined with Lobeglitazone.Approved
LofentanilThe risk or severity of adverse effects can be increased when Clozapine is combined with Lofentanil.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Clozapine is combined with Lofexidine.Approved, Investigational
LomitapideThe serum concentration of Clozapine can be increased when it is combined with Lomitapide.Approved
LomustineThe risk or severity of adverse effects can be increased when Lomustine is combined with Clozapine.Approved
LoperamideThe serum concentration of Clozapine can be increased when it is combined with Loperamide.Approved
LopinavirThe metabolism of Clozapine can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Clozapine is combined with Loprazolam.Experimental
LoratadineThe serum concentration of Clozapine can be increased when it is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Clozapine.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Clozapine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Clozapine.Approved
LosartanThe serum concentration of Clozapine can be increased when it is combined with Losartan.Approved
LovastatinThe metabolism of Clozapine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Loxapine.Approved
LuliconazoleThe serum concentration of Clozapine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Clozapine can be increased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Clozapine can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Clozapine is combined with Lurasidone.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Clozapine.Illicit, Withdrawn
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Clozapine.Approved, Vet Approved
ManidipineThe metabolism of Clozapine can be decreased when combined with Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Clozapine is combined with Mannitol.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Clozapine.Approved
MebendazoleThe serum concentration of Clozapine can be increased when it is combined with Mebendazole.Approved, Vet Approved
MebicarThe risk or severity of adverse effects can be increased when Clozapine is combined with Mebicar.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Clozapine is combined with Mecamylamine.Approved
MechlorethamineThe risk or severity of adverse effects can be increased when Mechlorethamine is combined with Clozapine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Clozapine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Clozapine.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Clozapine is combined with Medetomidine.Vet Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Clozapine.Approved
Megestrol acetateThe serum concentration of Clozapine can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Clozapine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Clozapine is combined with Melperone.Approved
MelphalanThe risk or severity of adverse effects can be increased when Melphalan is combined with Clozapine.Approved
MephedroneClozapine may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineClozapine may decrease the stimulatory activities of Mephentermine.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Clozapine.Investigational, Withdrawn
MepivacaineThe risk or severity of adverse effects can be increased when Clozapine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe serum concentration of Clozapine can be increased when it is combined with Meprobamate.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Clozapine is combined with Meptazinol.Experimental
MequitazineClozapine may increase the arrhythmogenic activities of Mequitazine.Approved
MercaptopurineThe risk or severity of adverse effects can be increased when Mercaptopurine is combined with Clozapine.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Clozapine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Clozapine is combined with Metaxalone.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Clozapine.Experimental
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Clozapine.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Clozapine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Clozapine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Clozapine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Clozapine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Clozapine is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Clozapine is combined with Methazolamide.Approved
MethimazoleThe risk or severity of adverse effects can be increased when Methimazole is combined with Clozapine.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Clozapine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Clozapine is combined with Methohexital.Approved
MethotrexateThe risk or severity of adverse effects can be increased when Methotrexate is combined with Clozapine.Approved
MethotrimeprazineClozapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Clozapine.Approved, Vet Approved
MethoxyphenamineClozapine may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Clozapine is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Clozapine is combined with Methyclothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Clozapine is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Clozapine is combined with Methylecgonine.Experimental
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Clozapine.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Clozapine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Clozapine is combined with Methylphenobarbital.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Clozapine.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Clozapine.Approved
MetipranololThe risk or severity of adverse effects can be increased when Clozapine is combined with Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Clozapine.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Clozapine is combined with Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Clozapine.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Clozapine.Approved
MetyrosineClozapine may increase the sedative activities of Metyrosine.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Clozapine.Experimental
MexiletineThe serum concentration of Clozapine can be increased when it is combined with Mexiletine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Clozapine.Approved
MibefradilThe serum concentration of Clozapine can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Clozapine can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Clozapine.Approved, Illicit
MidomafetamineClozapine may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
MidostaurinThe serum concentration of Clozapine can be increased when it is combined with Midostaurin.Approved
MifepristoneThe serum concentration of Clozapine can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Clozapine.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Clozapine.Approved
MilnacipranThe serum concentration of Clozapine can be increased when it is combined with Milnacipran.Approved
MinaprineThe metabolism of Minaprine can be decreased when combined with Clozapine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clozapine.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Clozapine is combined with Minoxidil.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Clozapine.Approved
MirtazapineClozapine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Clozapine.Approved, Investigational
MitomycinThe risk or severity of adverse effects can be increased when Mitomycin is combined with Clozapine.Approved
MitoxantroneThe risk or severity of adverse effects can be increased when Mitoxantrone is combined with Clozapine.Approved, Investigational
MMDAClozapine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Clozapine.Approved
ModafinilThe metabolism of Clozapine can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Clozapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Clozapine is combined with Molindone.Approved
MorphineThe serum concentration of Clozapine can be increased when it is combined with Morphine.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Clozapine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Clozapine is combined with Moxonidine.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Clozapine.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Clozapine is combined with Nadolol.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Clozapine is combined with Nalbuphine.Approved
NaltrexoneThe serum concentration of Clozapine can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Clozapine.Approved, Investigational
NaringeninThe serum concentration of Clozapine can be increased when it is combined with Naringenin.Experimental
NateglinideThe metabolism of Nateglinide can be decreased when combined with Clozapine.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Clozapine.Approved, Investigational
NefazodoneThe metabolism of Clozapine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelarabineThe risk or severity of adverse effects can be increased when Nelarabine is combined with Clozapine.Approved, Investigational
NelfinavirThe metabolism of Clozapine can be decreased when combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Clozapine can be increased when it is combined with Neostigmine.Approved, Vet Approved
NesiritideThe risk or severity of adverse effects can be increased when Clozapine is combined with Nesiritide.Approved, Investigational
NetazepideThe risk or severity of adverse effects can be increased when Netazepide is combined with Clozapine.Investigational
NetupitantThe serum concentration of Clozapine can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Clozapine can be decreased when it is combined with Nevirapine.Approved
NicardipineThe metabolism of Clozapine can be decreased when combined with Nicardipine.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Clozapine.Approved
NicorandilNicorandil may increase the hypotensive activities of Clozapine.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Clozapine.Approved
NifedipineThe serum concentration of Clozapine can be decreased when it is combined with Nifedipine.Approved
NilotinibThe risk or severity of adverse effects can be increased when Nilotinib is combined with Clozapine.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Clozapine is combined with Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Clozapine is combined with Nimodipine.Approved
NisoldipineThe serum concentration of Clozapine can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Clozapine.Approved
NitrendipineThe serum concentration of Clozapine can be increased when it is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Clozapine is combined with Nitric Oxide.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Clozapine.Approved, Vet Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Clozapine is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Clozapine is combined with Nitroprusside.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Clozapine is combined with Nitrous oxide.Approved, Vet Approved
NorethisteroneThe serum concentration of Clozapine can be decreased when it is combined with Norethisterone.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Clozapine.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Clozapine is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Clozapine is combined with Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the QTc-prolonging activities of Clozapine.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Clozapine.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Clozapine.Approved, Investigational
OfloxacinClozapine may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Clozapine.Approved, Investigational
OlaparibThe risk or severity of adverse effects can be increased when Olaparib is combined with Clozapine.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Clozapine is combined with Olmesartan.Approved, Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Clozapine.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Clozapine is combined with Olopatadine.Approved
OmeprazoleThe serum concentration of Clozapine can be decreased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronClozapine may increase the QTc-prolonging activities of Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Clozapine is combined with Opium.Approved, Illicit
OrphenadrineClozapine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Clozapine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Clozapine can be increased when it is combined with Osimertinib.Approved
OxaliplatinThe risk or severity of adverse effects can be increased when Oxaliplatin is combined with Clozapine.Approved, Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Clozapine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Clozapine is combined with Oxethazaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Clozapine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Clozapine is combined with Oxybuprocaine.Approved
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Clozapine.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Clozapine.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Clozapine.Approved, Vet Approved
P-NitrophenolThe serum concentration of Clozapine can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Clozapine.Approved, Vet Approved
PalbociclibThe serum concentration of Clozapine can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Clozapine is combined with Paliperidone.Approved
Palmitic AcidThe serum concentration of Clozapine can be increased when it is combined with Palmitic Acid.Experimental
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Clozapine.Approved, Investigational
PanobinostatThe serum concentration of Clozapine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Clozapine can be increased when it is combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Clozapine is combined with Papaverine.Approved
ParaldehydeClozapine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe serum concentration of Clozapine can be increased when it is combined with Paroxetine.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Clozapine.Approved
PazopanibClozapine may increase the QTc-prolonging activities of Pazopanib.Approved
Peginterferon alfa-2aThe risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Clozapine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Clozapine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PemetrexedThe risk or severity of adverse effects can be increased when Pemetrexed is combined with Clozapine.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Clozapine is combined with Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Clozapine is combined with Penfluridol.Experimental
PentamidineClozapine may increase the QTc-prolonging activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Clozapine is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe serum concentration of Clozapine can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PentostatinThe risk or severity of adverse effects can be increased when Pentostatin is combined with Clozapine.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Clozapine.Approved
PerazineThe risk or severity of adverse effects can be increased when Clozapine is combined with Perazine.Investigational
PerflutrenClozapine may increase the QTc-prolonging activities of Perflutren.Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Clozapine.Approved, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Clozapine.Approved
PerindoprilThe serum concentration of Clozapine can be increased when it is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Clozapine is combined with Perospirone.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Clozapine.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Clozapine.Approved
PF-477736The risk or severity of adverse effects can be increased when PF-477736 is combined with Clozapine.Investigational
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Clozapine.Withdrawn
PhenazocineThe risk or severity of adverse effects can be increased when Clozapine is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Clozapine.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Clozapine.Approved, Withdrawn
PhenibutThe risk or severity of adverse effects can be increased when Clozapine is combined with Phenibut.Experimental
PhenobarbitalThe serum concentration of Clozapine can be decreased when it is combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Clozapine is combined with Phenoperidine.Experimental
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Clozapine is combined with Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Clozapine is combined with Phenoxyethanol.Approved
PhentermineClozapine may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhentolamineThe risk or severity of adverse effects can be increased when Clozapine is combined with Phentolamine.Approved
PhenytoinThe serum concentration of Clozapine can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PibrentasvirThe serum concentration of Clozapine can be increased when it is combined with Pibrentasvir.Approved
PimozideThe serum concentration of Clozapine can be increased when it is combined with Pimozide.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Clozapine.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Clozapine.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Clozapine is combined with Pipamperone.Approved
PiperazineThe metabolism of Piperazine can be decreased when combined with Clozapine.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Clozapine.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Clozapine.Approved
PiribedilThe therapeutic efficacy of Piribedil can be decreased when used in combination with Clozapine.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Clozapine is combined with Piritramide.Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Clozapine.Approved
PizotifenThe risk or severity of adverse effects can be increased when Clozapine is combined with Pizotifen.Approved
Platelet Activating FactorThe serum concentration of Clozapine can be decreased when it is combined with Platelet Activating Factor.Experimental
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Clozapine.Approved
PonatinibThe risk or severity of adverse effects can be increased when Ponatinib is combined with Clozapine.Approved
PosaconazoleThe metabolism of Clozapine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleClozapine may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Clozapine.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Clozapine is combined with Pramocaine.Approved
PravastatinThe serum concentration of Clozapine can be increased when it is combined with Pravastatin.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Clozapine.Approved, Illicit
PrazosinThe serum concentration of Clozapine can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Clozapine can be increased when it is combined with Prednisone.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Clozapine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Clozapine is combined with Prilocaine.Approved
PrimaquineClozapine may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe serum concentration of Clozapine can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Clozapine can be increased when it is combined with Probenecid.Approved
ProcainamideThe metabolism of Procainamide can be decreased when combined with Clozapine.Approved
ProcaineThe risk or severity of adverse effects can be increased when Clozapine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Clozapine.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Clozapine.Approved, Vet Approved
ProgesteroneThe serum concentration of Clozapine can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromazineClozapine may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Clozapine.Approved
PropafenoneThe serum concentration of Clozapine can be increased when it is combined with Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Clozapine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Clozapine is combined with Proparacaine.Approved, Vet Approved
PropofolPropofol may increase the QTc-prolonging activities of Clozapine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Clozapine is combined with Propoxycaine.Approved
PropranololThe serum concentration of Clozapine can be increased when it is combined with Propranolol.Approved, Investigational
PropylthiouracilThe risk or severity of adverse effects can be increased when Propylthiouracil is combined with Clozapine.Approved
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Clozapine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Clozapine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Clozapine is combined with PSD502.Investigational
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Clozapine.Approved
PyrimethamineThe metabolism of Clozapine can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe risk or severity of adverse effects can be increased when Clozapine is combined with Quazepam.Approved, Illicit
QuercetinThe serum concentration of Clozapine can be increased when it is combined with Quercetin.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Quetiapine.Approved
QuinacrineThe serum concentration of Clozapine can be increased when it is combined with Quinacrine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Clozapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Clozapine is combined with Quinapril.Approved, Investigational
QuinidineThe metabolism of Clozapine can be decreased when combined with Quinidine.Approved
QuinineThe serum concentration of Clozapine can be increased when it is combined with Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Clozapine is combined with Quinisocaine.Experimental
RabeprazoleThe metabolism of Clozapine can be decreased when combined with Rabeprazole.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Clozapine is combined with Raclopride.Investigational
RaltitrexedThe risk or severity of adverse effects can be increased when Raltitrexed is combined with Clozapine.Approved, Investigational
RamelteonThe risk or severity of adverse effects can be increased when Clozapine is combined with Ramelteon.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Clozapine is combined with Ramipril.Approved
RanitidineThe serum concentration of Clozapine can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Clozapine can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Clozapine.Approved
ReboxetineThe serum concentration of Clozapine can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Clozapine can be increased when it is combined with Regorafenib.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Clozapine is combined with Remifentanil.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Clozapine.Approved, Withdrawn
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Clozapine.Approved, Investigational
repinotanThe metabolism of repinotan can be decreased when combined with Clozapine.Investigational
ReserpineThe serum concentration of Clozapine can be decreased when it is combined with Reserpine.Approved
RifabutinThe serum concentration of Clozapine can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Clozapine can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Clozapine can be decreased when it is combined with Rifapentine.Approved
RilpivirineRilpivirine may increase the QTc-prolonging activities of Clozapine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Clozapine is combined with Riociguat.Approved
RisperidoneClozapine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Clozapine is combined with Ritanserin.Investigational
RitobegronClozapine may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe metabolism of Clozapine can be decreased when combined with Ritonavir.Approved, Investigational
RituximabThe risk or severity of adverse effects can be increased when Rituximab is combined with Clozapine.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Clozapine.Approved
RolapitantThe serum concentration of Clozapine can be increased when it is combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Clozapine is combined with Romifidine.Vet Approved
RopiniroleClozapine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Clozapine.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Clozapine.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Clozapine.Approved
RotigotineClozapine may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Rucaparib can be decreased when combined with Clozapine.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Clozapine.Approved
RupatadineThe metabolism of Rupatadine can be decreased when combined with Clozapine.Approved
RuxolitinibThe risk or severity of adverse effects can be increased when Ruxolitinib is combined with Clozapine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Clozapine is combined with Sacubitril.Approved
SalbutamolSalbutamol may increase the QTc-prolonging activities of Clozapine.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Clozapine.Approved
SaquinavirClozapine may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Clozapine.Approved
ScopolamineThe serum concentration of Clozapine can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Clozapine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe serum concentration of Clozapine can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Clozapine is combined with Sepranolone.Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Clozapine.Approved, Withdrawn
SertralineThe serum concentration of Clozapine can be increased when it is combined with Sertraline.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Clozapine.Approved, Vet Approved
SildenafilThe metabolism of Clozapine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Clozapine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Clozapine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Clozapine can be increased when it is combined with Simvastatin.Approved
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Clozapine.Approved, Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Clozapine.Approved, Investigational
SJG-136The risk or severity of adverse effects can be increased when SJG-136 is combined with Clozapine.Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Clozapine is combined with Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Clozapine.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Clozapine.Approved
SorafenibThe risk or severity of adverse effects can be increased when Sorafenib is combined with Clozapine.Approved, Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Clozapine.Investigational
SotalolThe risk or severity of adverse effects can be increased when Clozapine is combined with Sotalol.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Clozapine.Experimental
SpironolactoneThe serum concentration of Clozapine can be increased when it is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Clozapine can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Clozapine can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Clozapine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Clozapine is combined with Streptokinase.Approved
StreptozocinThe risk or severity of adverse effects can be increased when Streptozocin is combined with Clozapine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Clozapine is combined with Sufentanil.Approved, Investigational
SulfadiazineThe metabolism of Clozapine can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Clozapine.Approved
SulfinpyrazoneThe serum concentration of Clozapine can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Clozapine.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Clozapine.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Clozapine is combined with Sulpiride.Approved
SultoprideThe risk or severity of adverse effects can be increased when Clozapine is combined with Sultopride.Experimental
SumatriptanThe serum concentration of Clozapine can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Clozapine.Approved, Investigational
SuvorexantClozapine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrineThe serum concentration of Clozapine can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Clozapine.Approved, Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Clozapine resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Clozapine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Clozapine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Clozapine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Clozapine is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Clozapine can be increased when it is combined with Taurocholic Acid.Experimental
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Clozapine.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Clozapine.Investigational, Withdrawn
TelaprevirThe metabolism of Clozapine can be decreased when combined with Telaprevir.Withdrawn
TelavancinClozapine may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinClozapine may increase the QTc-prolonging activities of Telithromycin.Approved
TelmisartanThe serum concentration of Clozapine can be increased when it is combined with Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Clozapine.Approved
TemozolomideThe risk or severity of adverse effects can be increased when Temozolomide is combined with Clozapine.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Clozapine.Approved
TeniposideThe risk or severity of adverse effects can be increased when Teniposide is combined with Clozapine.Approved
Tenofovir disoproxilThe metabolism of Clozapine can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerazosinThe serum concentration of Clozapine can be increased when it is combined with Terazosin.Approved
TerbinafineThe metabolism of Clozapine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Clozapine.Approved
TerfenadineThe serum concentration of Clozapine can be increased when it is combined with Terfenadine.Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Clozapine.Experimental
TeriflunomideThe serum concentration of Clozapine can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Clozapine can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Clozapine can be increased when it is combined with Testosterone.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Clozapine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Clozapine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Clozapine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Clozapine is combined with Tetrodotoxin.Investigational
ThalidomideClozapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Clozapine can be decreased when combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Clozapine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Clozapine is combined with Thiopental.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Clozapine.Withdrawn
ThiotepaThe risk or severity of adverse effects can be increased when Thiotepa is combined with Clozapine.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Clozapine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Clozapine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Clozapine is combined with Tiapride.Approved, Investigational
TicagrelorThe serum concentration of Clozapine can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Clozapine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Clozapine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Clozapine is combined with Tilidine.Experimental
TimololThe metabolism of Timolol can be decreased when combined with Clozapine.Approved
TioguanineThe risk or severity of adverse effects can be increased when Tioguanine is combined with Clozapine.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Clozapine.Approved
TipranavirThe metabolism of Clozapine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Clozapine.Approved
TocilizumabThe serum concentration of Clozapine can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe risk or severity of adverse effects can be increased when Tofacitinib is combined with Clozapine.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Clozapine.Approved
TolazolineThe risk or severity of adverse effects can be increased when Clozapine is combined with Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Clozapine can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Clozapine is combined with Tolcapone.Approved, Withdrawn
TolterodineTolterodine may increase the QTc-prolonging activities of Clozapine.Approved, Investigational
TolvaptanThe serum concentration of Clozapine can be increased when it is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Clozapine is combined with Topiramate.Approved
TopiroxostatThe metabolism of Clozapine can be decreased when combined with Topiroxostat.Approved
TopotecanThe risk or severity of adverse effects can be increased when Topotecan is combined with Clozapine.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Clozapine is combined with Torasemide.Approved
ToremifeneClozapine may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TositumomabThe risk or severity of adverse effects can be increased when Tositumomab is combined with Clozapine.Approved
TrabectedinThe risk or severity of adverse effects can be increased when Trabectedin is combined with Clozapine.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Clozapine.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Clozapine is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Clozapine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe metabolism of Clozapine can be decreased when combined with Tranylcypromine.Approved
Trastuzumab emtansineThe risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Clozapine.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Clozapine.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Clozapine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Clozapine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Clozapine is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Clozapine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Clozapine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Clozapine is combined with Trichloroethylene.Experimental
TrifluoperazineThe serum concentration of Clozapine can be increased when it is combined with Trifluoperazine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Clozapine is combined with Trifluperidol.Experimental
TriflupromazineThe serum concentration of Clozapine can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Clozapine.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Clozapine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Clozapine is combined with Triprolidine.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Clozapine.Approved, Vet Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Clozapine.Withdrawn
TroleandomycinThe serum concentration of Clozapine can be increased when it is combined with Troleandomycin.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Clozapine.Experimental
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Clozapine.Approved
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Clozapine.Approved, Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Clozapine is combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Clozapine can be decreased when combined with Valsartan.Approved, Investigational
VandetanibClozapine may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Clozapine.Approved
VelpatasvirThe serum concentration of Clozapine can be increased when it is combined with Velpatasvir.Approved
VemurafenibThe serum concentration of Clozapine can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe serum concentration of Clozapine can be increased when it is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Clozapine is combined with Veralipride.Experimental
VerapamilThe metabolism of Clozapine can be decreased when combined with Verapamil.Approved
VernakalantThe metabolism of Vernakalant can be decreased when combined with Clozapine.Approved, Investigational
VigabatrinThe risk or severity of adverse effects can be increased when Clozapine is combined with Vigabatrin.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Clozapine.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Clozapine.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Clozapine.Approved, Investigational
VinblastineThe risk or severity of adverse effects can be increased when Vinblastine is combined with Clozapine.Approved
VincristineThe serum concentration of Clozapine can be decreased when it is combined with Vincristine.Approved, Investigational
VindesineThe risk or severity of adverse effects can be increased when Vindesine is combined with Clozapine.Approved
VinorelbineThe risk or severity of adverse effects can be increased when Vinorelbine is combined with Clozapine.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Clozapine is combined with Vinyl ether.Experimental
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Clozapine.Approved, Investigational
VoriconazoleThe metabolism of Clozapine can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatThe risk or severity of adverse effects can be increased when Vorinostat is combined with Clozapine.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Clozapine.Approved
VoxilaprevirThe serum concentration of Clozapine can be increased when it is combined with Voxilaprevir.Approved
XenonThe risk or severity of adverse effects can be increased when Clozapine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Clozapine is combined with Xylazine.Vet Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Clozapine.Approved, Vet Approved
ZafirlukastThe metabolism of Clozapine can be decreased when combined with Zafirlukast.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Clozapine.Approved
ZaleplonThe risk or severity of adverse effects can be increased when Clozapine is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Clozapine is combined with Ziconotide.Approved
ZidovudineThe risk or severity of adverse effects can be increased when Zidovudine is combined with Clozapine.Approved
ZimelidineThe serum concentration of Clozapine can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Clozapine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Clozapine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Clozapine.Approved, Investigational
ZolpidemClozapine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Clozapine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Clozapine is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Clozapine is combined with Zotepine.Approved
ZucapsaicinThe metabolism of Clozapine can be decreased when combined with Zucapsaicin.Approved
ZuclopenthixolThe metabolism of Zuclopenthixol can be decreased when combined with Clozapine.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Limit caffeine intake (may reduce clozapine matabolism).
  • Take without regard to meals.

References

Synthesis Reference

Schmutz, J. and Hunziker, F.; US. Patent 3,539,573; November 10, 1970 .

US3539573
General References
  1. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA: Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med. 1993 Jul 15;329(3):162-7. [PubMed:8515788]
  2. Vaddadi KS, Soosai E, Vaddadi G: Low blood selenium concentrations in schizophrenic patients on clozapine. Br J Clin Pharmacol. 2003 Mar;55(3):307-9. [PubMed:12630982]
  3. Naheed M, Green B: Focus on clozapine. Curr Med Res Opin. 2001;17(3):223-9. [PubMed:11900316]
  4. Lane HY, Chang YC, Chang WH, Lin SK, Tseng YT, Jann MW: Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. J Clin Psychiatry. 1999 Jan;60(1):36-40. [PubMed:10074876]
External Links
Human Metabolome Database
HMDB14507
KEGG Drug
D00283
KEGG Compound
C06924
PubChem Compound
2818
PubChem Substance
46506474
ChemSpider
10442628
BindingDB
50001884
ChEBI
3766
ChEMBL
CHEMBL42
Therapeutic Targets Database
DAP000029
PharmGKB
PA449061
IUPHAR
38
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Clozapine
ATC Codes
N05AH02 — Clozapine
AHFS Codes
  • 28:16.08.04 — Atypical Antipsychotics
FDA label
Download (89.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceSchizophrenic Disorders1
1, 2CompletedTreatmentSchizophrenic Disorders1
2CompletedTreatmentBipolar Disorder (BD)1
2CompletedTreatmentSchizophrenic Disorders1
3CompletedTreatmentBipolar Disorder (BD)1
3CompletedTreatmentDevelopmental Delay Disorders / Mental Retardation1
3CompletedTreatmentSchizophrenic Disorders2
3RecruitingTreatmentAnxiety Disorders / Dementias / Depressive State / Psychosomatic Disorders / Schizophrenic Disorders1
3Unknown StatusTreatmentPsychosis Nos/Other1
3WithdrawnTreatmentSchizophrenic Disorders2
4Active Not RecruitingNot AvailablePsychotic Disorder NOS / Schizophrenic Disorders1
4Active Not RecruitingTreatmentCannabis Abuse / Cannabis Dependence / Dual Diagnosis / Schizophrenic Disorders1
4CompletedBasic ScienceSchizoaffective Disorders / Schizophrenic Disorders1
4CompletedHealth Services ResearchSchizophrenic Disorders1
4CompletedTreatmentCannabis Abuse / Dual Diagnosis / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders1
4CompletedTreatmentMetabolic Syndromes1
4CompletedTreatmentPanic Disorders1
4CompletedTreatmentPsychotic Disorder NOS / Schizophrenia, Childhood / Schizophrenic Disorders1
4CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders2
4CompletedTreatmentSchizophrenic Disorders6
4RecruitingTreatmentBipolar Disorder (BD)1
4RecruitingTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
4TerminatedTreatmentSchizophrenic Disorders2
Not AvailableCompletedNot AvailableBipolar Disorder (BD) / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Type 2 Diabetes Mellitus1
Not AvailableCompletedTreatmentCannabis-Related Disorder / Psychotic Disorder NOS / Schizophrenic Disorders / Substance-Related Disorders1
Not AvailableCompletedTreatmentParkinson's Disease (PD)1
Not AvailableCompletedTreatmentSchizophrenic Disorders3
Not AvailableEnrolling by InvitationNot AvailableBipolar Disorder (BD)1
Not AvailableRecruitingNot AvailableAcute Bacterial Exacerbation of Chronic Bronchitis (ABECB) / Acute Bacterial Sinusitis (ABS) / Acute Decompensated Heart Failure (ADHF) / Acute Pyelonephritis / Adenovirus / Adjunct to general anesthesia therapy / Adrenal Insufficiency / Airway Swelling / Anaesthesia therapy / Anxiolysis / Arterial Hypotension / Autism, Early Infantile / Autistic Disorder / Bartonellosis / Benzodiazepine Withdrawal / Benzodiazepines / Bipolar Disorder (BD) / Bloodstream Infections / Bone and Joint Infections / Brain Swelling / Bronchospasm / Brucellosis / Cardiac Arrest / Central Nervous System Infections / Cholera / Chronic Bacterial Prostatitis / Community Acquired Pneumonia (CAP) / Complicated Urinary Tract Infections / Convulsions / Cyanide Poisoning / Cytomegalovirus Retinitis / Drug hypersensitivity reaction / Early-onset Schizophrenia Spectrum Disorders / Edema / Epilepsies / Feeling Anxious / Flu caused by Influenza / Gastroparesis / GYNAECOLOGICAL INFECTION / Headaches / Herpes Simplex Virus / Hospital-acquired bacterial pneumonia / Hypercholesterolaemia / Hyperlipidemias / Hypertensive / Infantile Hemangiomas / Infection NOS / Inflammatory Conditions / Inflammatory Reaction / Influenza Treatment or Prophylaxis / Inhalational Anthrax (Post-Exposure) / Intra-Abdominal Infections / Life-threatening Fungal Infections / Lower Respiratory Tract Infection (LRTI) / Meningitis, Bacterial / Migraines / Muscle Spasms / Nausea / Opioid Addiction / Pain / Plague / Pneumonia / Prophylaxis / Psittacosis / Q Fever / Reflux / Relapsing Fever / Rocky Mountain Spotted Fever / Schizophrenic Disorders / Sedation therapy / Seizures / Sepsis / Skeletal Muscle Spasms / Skin and Subcutaneous Tissue Bacterial Infections / Skin Structures and Soft Tissue Infections / Stable Angina (SA) / Thromboprophylaxis / Thrombosis / Trachoma / Treatment-resistant Schizophrenia / Tularemia / Typhus Fever / Uncomplicated Skin and Skin Structure Infections / Uncomplicated Urinary Tract Infections / Urinary Tract Infections (UTIs) / Vomiting / Withdrawal1
Not AvailableRecruitingNot AvailableBipolar Disorder (BD)1
Not AvailableRecruitingNot AvailableSchizophrenic Disorders2
Not AvailableRecruitingTreatmentSchizophrenic Disorders1
Not AvailableUnknown StatusBasic ScienceSchizoaffective Disorders / Schizophrenic Disorders1
Not AvailableWithdrawnTreatmentSchizophrenic Disorders / Treatment Resistant Disorders1

Pharmacoeconomics

Manufacturers
  • Azur pharma international iii ltd
  • Caraco pharmaceutical laboratories ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Par pharmaceutical
  • Sandoz inc
  • Novartis pharmaceuticals corp
Packagers
Dosage forms
FormRouteStrength
TabletOral200 mg/1
TabletOral50 mg/1
Tablet, orally disintegratingOral100 mg/1
TabletOral100 mg/1
TabletOral25 mg/1
Tablet, orally disintegratingOral12.5 mg/1
Tablet, orally disintegratingOral150 mg/1
Tablet, orally disintegratingOral200 mg/1
Tablet, orally disintegratingOral25 mg/1
SuspensionOral50 mg
TabletOral100 mg
TabletOral200 mg
TabletOral25 mg
TabletOral50 mg
SuspensionOral50 mg/mL
Prices
Unit descriptionCostUnit
Fazaclo 100 mg odt6.55USD tablet
Clozapine 200 mg tablet6.32USD tablet
Clozaril 100 mg tablet5.84USD tablet
Clozapine 100 mg tablet3.33USD tablet
Apo-Clozapine 100 mg Tablet2.77USD tablet
Gen-Clozapine 100 mg Tablet2.77USD tablet
Fazaclo 25 mg odt2.4USD tablet
Fazaclo 25 mg tablet2.19USD tablet
Clozaril 25 mg tablet1.96USD tablet
Fazaclo 12.5 mg odt1.79USD tablet
Clozapine 50 mg tablet1.65USD tablet
Clozapine 25 mg tablet1.28USD tablet
Apo-Clozapine 25 mg Tablet0.69USD tablet
Gen-Clozapine 25 mg Tablet0.69USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5178878No1993-01-122010-01-12Us
US6221392No1998-04-092018-04-09Us
US6024981No1998-04-092018-04-09Us
US6106861No1997-12-052017-12-05Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)183-184 °CPhysProp
water solubility11.8 mg/LNot Available
logP3.23HANSCH,C ET AL. (1995)
pKa7.5EL TAYAR,N ET AL. (1985)
Predicted Properties
PropertyValueSource
Water Solubility0.186 mg/mLALOGPS
logP3.67ALOGPS
logP3.4ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)15.9ChemAxon
pKa (Strongest Basic)7.35ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area30.87 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity97.36 m3·mol-1ChemAxon
Polarizability35.77 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9904
Blood Brain Barrier+0.9614
Caco-2 permeable+0.6151
P-glycoprotein substrateSubstrate0.8684
P-glycoprotein inhibitor IInhibitor0.6791
P-glycoprotein inhibitor IIInhibitor0.7407
Renal organic cation transporterInhibitor0.8049
CYP450 2C9 substrateNon-substrate0.7509
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.6088
CYP450 1A2 substrateInhibitor0.5722
CYP450 2C9 inhibitorNon-inhibitor0.9432
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.9137
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.571
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9106
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.0838 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8189
hERG inhibition (predictor II)Inhibitor0.7164
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0090000000-bc2ca4d5a76a5facf897
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0009000000-986bc19f7e7e8602d005
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00b9-0049000000-d6315d4aeb74c251e939
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0090000000-27fd28450826291cc8c6
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0290000000-474b25ea27690471db0f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-0970000000-a58015260aaddb4245bd
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-0930000000-3ccfd048a34fdb4f594f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0009000000-7df53c42e3b1618bfdec
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0049000000-7522cc8ebf988effc792
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0090000000-bd138be4ae488c201ed3
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0190000000-68c8b78f304c38b7b7b5
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-0980000000-a9dd724f32c02059c510
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-0930000000-61c0f65f163824ddd594
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0090000000-da747a0572aa2c21683f
MS/MS Spectrum - , positiveLC-MS/MSsplash10-002f-0930000000-614883dbe075268cf23a
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00b9-0298000000-50d2ee0b52827fd1aee3
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00di-2690000000-daaa74a4f85f5e8b5926

Taxonomy

Description
This compound belongs to the class of organic compounds known as dibenzodiazepines. These are compounds containing a dibenzodiazepine moiety, which consists of two benzene connected by diazepine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzodiazepines
Sub Class
Dibenzodiazepines
Direct Parent
Dibenzodiazepines
Alternative Parents
1,4-benzodiazepines / N-methylpiperazines / Imidolactams / Benzenoids / Aryl chlorides / Trialkylamines / Secondary amines / Propargyl-type 1,3-dipolar organic compounds / Carboxamidines / Azacyclic compounds
show 3 more
Substituents
Dibenzodiazepine / 1,4-benzodiazepine / N-methylpiperazine / N-alkylpiperazine / Aryl chloride / Aryl halide / 1,4-diazinane / Imidolactam / Piperazine / Benzenoid
show 16 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
N-arylpiperazine, organochlorine compound, N-methylpiperazine, benzodiazepine (CHEBI:3766)

Targets

Details
1. D(2) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Green AI, Salomon MS, Brenner MJ, Rawlins K: Treatment of schizophrenia and comorbid substance use disorder. Curr Drug Targets CNS Neurol Disord. 2002 Apr;1(2):129-39. [PubMed:12769622]
  2. Weizman T, Pick CG, Backer MM, Rigai T, Bloch M, Schreiber S: The antinociceptive effect of amisulpride in mice is mediated through opioid mechanisms. Eur J Pharmacol. 2003 Oct 8;478(2-3):155-9. [PubMed:14575800]
  3. Young RM, Lawford BR, Barnes M, Burton SC, Ritchie T, Ward WK, Noble EP: Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. Br J Psychiatry. 2004 Aug;185:147-51. [PubMed:15286066]
  4. Stonehouse AH, Jones FS: Bromocriptine and clozapine regulate dopamine 2 receptor gene expression in the mouse striatum. J Mol Neurosci. 2005;25(1):29-36. [PubMed:15781964]
  5. Takano A, Suhara T, Kusumi I, Takahashi Y, Asai Y, Yasuno F, Ichimiya T, Inoue M, Sudo Y, Koyama T: Time course of dopamine D2 receptor occupancy by clozapine with medium and high plasma concentrations. Prog Neuropsychopharmacol Biol Psychiatry. 2006 Jan;30(1):75-81. Epub 2005 Jul 22. [PubMed:16040180]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Goldstein JM: Quetiapine fumarate (Seroquel): a new atypical antipsychotic. Drugs Today (Barc). 1999 Mar;35(3):193-210. [PubMed:12973385]
  2. McDonald LM, Moran PM, Vythelingum GN, Joseph MH, Stephenson JD, Gray JA: Enhancement of latent inhibition by two 5-HT2A receptor antagonists only when given at both pre-exposure and conditioning. Psychopharmacology (Berl). 2003 Sep;169(3-4):321-31. Epub 2002 Aug 9. [PubMed:14530903]
  3. Broderick PA, Hope O, Okonji C, Rahni DN, Zhou Y: Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jan;28(1):157-71. [PubMed:14687870]
  4. Heiser P, Schulte E, Hausmann C, Becker R, Remschmidt H, Krieg JC, Vedder H: Effects of clozapine and its metabolites on the 5-HT2 receptor system in cortical and hippocampal cells in vitro. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Mar;28(2):297-302. [PubMed:14751426]
  5. Reist C, Mazzanti C, Vu R, Fujimoto K, Goldman D: Inter-relationships of intermediate phenotypes for serotonin function, impulsivity, and a 5-HT2A candidate allele: His452Tyr. Mol Psychiatry. 2004 Sep;9(9):871-8. [PubMed:15037867]
  6. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12. [PubMed:7520908]
Details
3. D(1A) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Details
4. D(3) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name
DRD3
Uniprot ID
P35462
Uniprot Name
D(3) dopamine receptor
Molecular Weight
44224.335 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Details
5. D(4) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Sh3 domain binding
Specific Function
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins ...
Gene Name
DRD4
Uniprot ID
P21917
Uniprot Name
D(4) dopamine receptor
Molecular Weight
48359.86 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Zhao AL, Zhao JP, Zhang YH, Xue ZM, Chen JD, Chen XG: Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine. Int J Neurosci. 2005 Nov;115(11):1539-47. [PubMed:16223700]
  3. Nakane M, Cowart MD, Hsieh GC, Miller L, Uchic ME, Chang R, Terranova MA, Donnelly-Roberts DL, Namovic MT, Miller TR, Wetter JM, Marsh K, Stewart AO, Brioni JD, Moreland RB: 2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist. Neuropharmacology. 2005 Jul;49(1):112-21. Epub 2005 Apr 1. [PubMed:15992586]
  4. Kuballa G, Nowak P, Labus L, Bortel A, Dabrowska J, Swoboda M, Kwiecinski A, Kostrzewa RM, Brus R: Central effects of nafadotride, a dopamine D3 receptor antagonist, in rats. Comparison with haloperidol and clozapine. Pharmacol Rep. 2005 Mar-Apr;57(2):161-9. [PubMed:15886414]
  5. Glatt SJ, Faraone SV, Tsuang MT: Schizophrenia is not associated with DRD4 48-base-pair-repeat length or individual alleles: results of a meta-analysis. Biol Psychiatry. 2003 Sep 15;54(6):629-35. [PubMed:13129658]
  6. Patel S, Chapman KL, Marston D, Hutson PH, Ragan CI: Pharmacological and functional characterisation of dopamine D4 receptors in the rat retina. Neuropharmacology. 2003 Jun;44(8):1038-46. [PubMed:12763097]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Hagino Y, Watanabe M: Effects of clozapine on the efflux of serotonin and dopamine in the rat brain: the role of 5-HT1A receptors. Can J Physiol Pharmacol. 2002 Dec;80(12):1158-66. [PubMed:12564641]
  2. Chou YH, Halldin C, Farde L: Occupancy of 5-HT1A receptors by clozapine in the primate brain: a PET study. Psychopharmacology (Berl). 2003 Mar;166(3):234-40. Epub 2003 Feb 13. [PubMed:12589516]
  3. Newman-Tancredi A, Rivet JM, Cussac D, Touzard M, Chaput C, Marini L, Millan MJ: Comparison of hippocampal G protein activation by 5-HT(1A) receptor agonists and the atypical antipsychotics clozapine and S16924. Naunyn Schmiedebergs Arch Pharmacol. 2003 Sep;368(3):188-99. Epub 2003 Aug 16. [PubMed:12923612]
  4. Zahorodna A, Bobula B, Grzegorzewska M, Tokarski K, Hess G: The influence of repeated administration of clozapine and haloperidol on the effects of the activation of 5-HT(1A), 5-HT(2) and 5-HT(4) receptors in rat frontal cortex. J Physiol Pharmacol. 2004 Jun;55(2):371-9. [PubMed:15213359]
  5. Tomic M, Kundakovic M, Butorovic B, Janac B, Andric D, Roglic G, Ignjatovic D, Kostic-Rajacic S: Pharmacological evaluation of selected arylpiperazines with atypical antipsychotic potential. Bioorg Med Chem Lett. 2004 Aug 16;14(16):4263-6. [PubMed:15261283]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1B
Uniprot ID
P28222
Uniprot Name
5-hydroxytryptamine receptor 1B
Molecular Weight
43567.535 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1D
Uniprot ID
P28221
Uniprot Name
5-hydroxytryptamine receptor 1D
Molecular Weight
41906.38 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that trig...
Gene Name
HTR1E
Uniprot ID
P28566
Uniprot Name
5-hydroxytryptamine receptor 1E
Molecular Weight
41681.57 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Sodhi MS, Airey DC, Lambert W, Burnet PW, Harrison PJ, Sanders-Bush E: A rapid new assay to detect RNA editing reveals antipsychotic-induced changes in serotonin-2C transcripts. Mol Pharmacol. 2005 Sep;68(3):711-9. Epub 2005 May 25. [PubMed:15917433]
  2. Navailles S, De Deurwaerdere P, Spampinato U: Clozapine and haloperidol differentially alter the constitutive activity of central serotonin2C receptors in vivo. Biol Psychiatry. 2006 Mar 15;59(6):568-75. Epub 2005 Sep 22. [PubMed:16182256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Voltage-gated potassium channel activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gate...
Gene Name
HTR3A
Uniprot ID
P46098
Uniprot Name
5-hydroxytryptamine receptor 3A
Molecular Weight
55279.835 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR6
Uniprot ID
P50406
Uniprot Name
5-hydroxytryptamine receptor 6
Molecular Weight
46953.625 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR7
Uniprot ID
P34969
Uniprot Name
5-hydroxytryptamine receptor 7
Molecular Weight
53554.43 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Details
14. Histamine H1 receptor
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Roegge CS, Perraut C, Hao X, Levin ED: Histamine H1 receptor involvement in prepulse inhibition and memory function: relevance for the antipsychotic actions of clozapine. Pharmacol Biochem Behav. 2007 Apr;86(4):686-92. Epub 2007 Feb 22. [PubMed:17382376]
  3. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12. [PubMed:7520908]
Details
15. Histamine H4 receptor
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
The H4 subclass of histamine receptors could mediate the histamine signals in peripheral tissues. Displays a significant level of constitutive activity (spontaneous activity in the absence of agoni...
Gene Name
HRH4
Uniprot ID
Q9H3N8
Uniprot Name
Histamine H4 receptor
Molecular Weight
44495.375 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Sugata Y, Okano M, Fujiwara T, Matsumoto R, Hattori H, Yamamoto M, Nishibori M, Nishizaki K: Histamine H4 receptor agonists have more activities than H4 agonism in antigen-specific human T-cell responses. Immunology. 2007 Jun;121(2):266-75. Epub 2007 Mar 7. [PubMed:17346280]
  3. Smits RA, Lim HD, Stegink B, Bakker RA, de Esch IJ, Leurs R: Characterization of the histamine H4 receptor binding site. Part 1. Synthesis and pharmacological evaluation of dibenzodiazepine derivatives. J Med Chem. 2006 Jul 27;49(15):4512-6. [PubMed:16854056]
  4. Adachi N, Liu K, Motoki A, Nishibori M, Arai T: Suppression of ischemia/reperfusion liver injury by histamine H4 receptor stimulation in rats. Eur J Pharmacol. 2006 Aug 21;544(1-3):181-7. Epub 2006 Jun 29. [PubMed:16860312]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Epinephrine binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name
ADRA2B
Uniprot ID
P18089
Uniprot Name
Alpha-2B adrenergic receptor
Molecular Weight
49565.8 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name
ADRA2C
Uniprot ID
P18825
Uniprot Name
Alpha-2C adrenergic receptor
Molecular Weight
49521.585 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM4
Uniprot ID
P08173
Uniprot Name
Muscarinic acetylcholine receptor M4
Molecular Weight
53048.65 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM5
Uniprot ID
P08912
Uniprot Name
Muscarinic acetylcholine receptor M5
Molecular Weight
60073.205 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Unknown
General Function
Clathrin light chain binding
Specific Function
Interacts with clathrin light chain A and stimulates clathrin self-assembly and clathrin-mediated endocytosis.
Gene Name
CALY
Uniprot ID
Q9NYX4
Uniprot Name
Neuron-specific vesicular protein calcyon
Molecular Weight
23433.49 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
S-nitrosoglutathione binding
Specific Function
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Regulates negatively CDK5 activity via p25/p35 translocation to prevent neurodegeneration.
Gene Name
GSTP1
Uniprot ID
P09211
Uniprot Name
Glutathione S-transferase P
Molecular Weight
23355.625 Da
References
  1. Boerma JS, Vermeulen NP, Commandeur JN: Application of CYP102A1M11H as a tool for the generation of protein adducts of reactive drug metabolites. Chem Res Toxicol. 2011 Aug 15;24(8):1263-74. doi: 10.1021/tx2001515. Epub 2011 Jun 16. [PubMed:21639118]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Brosen K: Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2. Clin Pharmacokinet. 1995;29 Suppl 1:20-5. [PubMed:8846619]
  2. Wang B, Zhou SF: Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218. [PubMed:19754423]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  4. Fang J, Coutts RT, McKenna KF, Baker GB: Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. Naunyn Schmiedebergs Arch Pharmacol. 1998 Nov;358(5):592-9. [PubMed:9840430]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  6. Carrillo JA, Benitez J: Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin Pharmacokinet. 2000 Aug;39(2):127-53. [PubMed:10976659]
  7. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Trimethylamine monooxygenase activity
Specific Function
Involved in the oxidative metabolism of a variety of xenobiotics such as drugs and pesticides. It N-oxygenates primary aliphatic alkylamines as well as secondary and tertiary amines. Plays an impor...
Gene Name
FMO3
Uniprot ID
P31513
Uniprot Name
Dimethylaniline monooxygenase [N-oxide-forming] 3
Molecular Weight
60032.975 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Protein homodimerization activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A4
Uniprot ID
P22310
Uniprot Name
UDP-glucuronosyltransferase 1-4
Molecular Weight
60024.535 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1B1
Uniprot ID
Q16678
Uniprot Name
Cytochrome P450 1B1
Molecular Weight
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Boulton DW, DeVane CL, Liston HL, Markowitz JS: In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002 May 31;71(2):163-9. [PubMed:12031686]

Drug created on June 13, 2005 07:24 / Updated on October 21, 2017 19:22